Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 49 for “"SN-38"”.
-
Progress towards hypoxia-activated SN-38: the potential to target hypoxic tumors
… of hypoxic cancer cells. With their parent drug SN-38 as an inhibitor of both topoisomerase 1 and HIF-1, hypoxia-activated SN-38s may have a dual inhibitory effect on hypoxic tumor cells due to hypoxia-targeting and HIF-1 inhibition. To develop hypoxia-activated prodrugs of SN-38; 2-, 3-, and …
-
Investigations into the Mechanisms that Are Responsible for Reduction in Colonic SN-38 Exposure
… population due to the high accumulation of SN-38 in colon. It has been hypothesized that multiple factors, such as higher biliary excretion of SN-38 and SN-38 glucuronide mediated through different efflux transporters, deglucuronidation of SN-38 glucuronide to SN-38 by bacterial …
-
Optimizing the encapsulation of SN-38 in PCL-b-PEG polymer nanoparticles for cancer therapy
… challenges encapsulating the anticancer agent, SN-38, in polymer nanoparticles (PNPs) for improved cancer treatment. SN-38 is particularly difficult to encapsulate due to its poor solubility in water and many solvents. Methods: PNPs were synthesized using both bulk and microfluidic …
-
Development of Novel Peptide-Drug Conjugates for Targeting Brain Tumors and Brain Metastases
… Irinotecan is the prodrug of anticancer drug SN-38 which stabilizes the topoisomerase I-DNA complex and inhibits the enzyme leading to DNA damaging. It is used as a first-line treatment for the advanced colorectal cancer. Despite their clinical use, there are several limitations of lapatinib …
-
The Combination of Carboxylesterase-Expressing Oncolytic Vaccinia Virus and Irinotecan
… is converted to the more active chemotherapeutic SN-38 by endogenous carboxylesterase (CE) enzymes. SN-38 is a topoisomerase I inhibitor that induces DNA double strand breaks, leading to growth arrest and apoptosis. Consequently, VV has been engineered to express a more effective isoform of the CE …
-
Effects of Inflammation and Soy Isoflavones on Irinotecan Pharmacokinetics and Toxicity
… and it is a prodrug to its cytotoxic metabolite SN-38 (7-ethyl-10-hydroxy-camptothecin), which is about 100-1000-fold more cytotoxic than irinotecan. Although irinotecan is a very potent chemotherapy drug, elevated blood concentrations of its active metabolite, SN-38 leads to increased …
-
Alterations in Colorectal Cancer Cell-extracellular Matrix Interactions Upon Acquisition of Chemotherapy Resistance.
… is highly resistant to its active metabolite (SN-38). In particular, we were interested in how SN-38 resistant CRC cells (HT-29S) were altered from parental, drug-sensitive CRC cells (HT-29) in their relationship with a feature of their microenvironment, the extracellular matrix (ECM). We found …
-
Synthesis and Characterization of Redox-Sensitive Polymer and Prodrug for Targeted Drug Delivery
… redox-sensitive self-immolative polymer, and DNS-SN38, thiol-sensitive SN-38 prodrug, as potential candidates for targeted drug delivery platforms. By covalently conjugating a redox-trigger (p-nitrobenzyl alcohol) and self-immolative linker (p-hydroxybenzyl alcohol) to the cyclization spacer …
-
Σχέση των πολυμορφισμών του γονιδίου UGT1A με την τοξικότητα της ιρινοτεκάνης (CPT-11) σε Έλληνες ασθενείς σε συμπαγείς όγκους
… of the active metabolite of the drug (SN-38) in the liver. UGT1A7 is believed to participate in the detoxification of SN-38 in the gut. UGT genepolymorphisms may lead to reduced transcription and activity of the enzymes and therefore reduceddetoxification of SN-38 and increased …
-
Avaliação genotípica e fenotípica da farmacocinética do irinotecano e sua relação com a ocorrência de toxicidade no tratamento do câncer
… pró-fármaco convertido em seu metabólito ativo SN-38 pela ação das carboxilesterases hepáticas. O SN-38 é o principal responsável pela resposta antitumoral do IRI e também pelas toxicidades limitantes da dose, neutropenia e diarreia. O polimorfismo UGT1A1 * 28 está associado a neutropenia grave …
-
Characterising changes in adhesion and enzyme activity related to drug resistance in colon cancer cells
… cancer treatments, into the active metabolite SN-38. Carboxylesterase enzymes are found in high quantities in both the liver and intestinal cells. The presence of carboxylesterase in intestinal and liver cells is an important consideration in the processing of colorectal cancer treatments. …
-
Microfluidic synthesis of drug-loaded block copolymer nanoparticles and its effect on drug delivery
… anti-cancer drug 7-ethyl-10-hydroxycamptothecin (SN-38) was physically encapsulated in poly(6-methyl-caprolactone-co-ε-caprolactone)-block-poly(ethylene oxide) (P(MCL-co-CL)-b-PEO) nanoparticles with various drug-to-polymer loading ratios, under different flow conditions. The effects of chemical …
-
Exploring the Bioactivity and Therapeutic Potential of Structurally Diverse Phytochemicals in Neurodegenerative and Gastrointestinal Disease
… of cytokine and 7-ethyl-10-hydroxycamptothecin (SN-38)-evoked decreases in epithelial barrier function in Caco-2 cells. We identified novel roles for CBD, CBG and CBDV as inhibitors of SN-38- evoked increases in permeability, with each phytocannabinoid screened, including CBC, inhibiting …
-
Untersuchungen zum morphologischen Ablauf und zur Regulation der mitotischen Katastrophe in Kolonkarzinomzellen nach Behandlung mit Irinotecan
… Irinotecan (CPT-11) sowie sein aktiver Metabolit SN-38 lösen in p53wt-Kolorektalkarzinomzelllinien einen lang anhaltenden Zellzyklusarrest und in p53mut-Zellen einen transienten Arrest aus, gefolgt von Apoptose. Da die meisten Kolonkarzinome im p53-Gen eine Mutation aufweisen, ist die …
-
Molecular Mechanisms of Irinotecan Induced Fatty Liver Disease and Drug-Drug Interaction
… in the liver to active and toxic metabolite, SN-38. The levels of SN-38 are determined by involvement of multiple DMEs, which includes, CYP3A, carboxylesterases (CES) and uridine diphosphate-glucuronosyltransferase (UGT1A1). We have previously shown that activation of TLR4 by LPS suppress DMEs …
-
A study linking toll-like receptors and irinotecan-induced gastrointestinal mucositis.
… the detoxification of the active metabolite SN-38 thus increasing the cytotoxicity of irinotecan. This could explain partially the histological damage, distress symptoms, inflammation and late diarrhoea occurrence after treatment with both drugs. The third study investigated the ability of …
-
Self-assembly Polymeric Nanoparticles Composed of Polymers Crosslinked with Transition Metals for Use in Drug Delivery
… encapsulated 7-ethyl-10-hydroxycampothecin (SN-38) into Co-alb NPs with encapsulation efficiency as high as 94% and loading capacities greater than 30%. We employed an emulsion-solvent evaporation method to incorporate SN-38 into Co-alb (SN38 Co-Alb NPs). Release of the drug from SN38 Co-Alb …
-
Correlating Irinotecan and Capecitabine Treatment for Colorectal Cancer to Gene Expression, Polymorphisms, and Clinical Outcomes
… are both prodrugs activated in vivo to SN-38 and 5-FU, respectively. Identification of the molecular markers for 5-FU and Irinotecan efficacy and toxicity is important for the development of more efficient and less toxic treatment strategies for patients with colorectal cancer. The goal …
Page 1 of 3